<DOC>
	<DOCNO>NCT00004436</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate clinical efficacy leuprolide , gonadotropin-releasing hormone agonist ( GnRHa ) , treat infant vision-endangering large , disfigure hemangioma . II . Assess impact GnRHa growth development infancy . III . Assess safety GnHRa patient .</brief_summary>
	<brief_title>Randomized Study Hormonal Regulation Infantile Hemangioma</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , placebo-controlled study . Patients stratify accord gender position lesion ( periorbital v nonperiorbital ) . All patient receive oral prednisone daily 3 week . Patients randomize receive either placebo leuprolide IM every 3 week , continue oral prednisone . Tumors assess 1 , 3 , 6 week . If tumor responding , leuprolide administer every 2 week . Tumors reassess 3 6 month , point treatment stop . Responding patient observe every 3 week 3 month . If tumor begin grow , leuprolide may administer another 3 month . Patients whose tumor grow rapidly treatment may crossover alternate therapy , repeat leuprolide prednisone therapy , undergo surgical excision .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Presence hemangioma meeting least one follow criterion : Visionthreatening induce astigmatism occlusion visual axis proptosis Severe anatomic distortion compromise function organ create unacceptable cosmetic outcome Other complication , e.g. , KasabachMerritt consumptive coagulopathy , highoutput heart failure , etc . No lesion clearly regress therapy No vascular malformation juvenile hemangioma</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>8 Months</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>hemangioma</keyword>
	<keyword>rare disease</keyword>
</DOC>